|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
52748298
???header.onlineuser??? :
692
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"ansell p"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
| 臺大學術典藏 |
2021-07-03T03:34:18Z |
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
|
Toh H.C.; PEI-JER CHEN; Carr B.I.; Knox J.J.; Gill S.; Ansell P.; McKeegan E.M.; Dowell B.; Pedersen M.; Qin Q.; Qian J.; Scappaticci F.A.; Ricker J.L.; Carlson D.M.; Yong W.P. |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
|
Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan R.K.; Strickler J.H; LoRusso P; Salgia R; Kang Y.-K; Yen C.J; Chia-Chi Lin |
| 國立成功大學 |
2020 |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler, J.H.;LoRusso, P.;Salgia, R.;Kang, Y.-K.;Yen, C.J.;Lin, C.-C.;Ansell, P.;Motwani, Motwani M.;Wong, S.;Yue, H.;Wang, L.;Reilly, E.;Afar, D.;Naumovski, L.;Ramanathan, Ramanathan R.K. |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
